ISIS,
More info from Tom Hua:
To:Paul A who wrote (12901)
From: Tom Hua Wednesday, Aug 22, 2001 8:53 PM
Respond to of 12944
Some magazine called it the next microsoft in a biotech kinda way : )
Paul, that may be a stretch but I think it's a nanosoft. Here's their product pipeline:
- Vitravene, commercial product, treats eye disease
- ISIS 3251, phase 3 trials, lung cancer treatment (license to Eli Lilly today)
- ISIS 2302 (P), phase 2 trials, Crohn's disease
- ISIS 2302 (T), phase 2, topical psorasis
- ISIS 14803, phase 2, Hepitatis C
- ISIS 2503, phase 2, pancreatic cancer
- ISIS 5132, phase 2, ovarian cancer
- ISIS 104838, phase 1, Crohn's disease, rheumatoid arthristis, phase 2 starts this year
- 4 more drugs in preclinical evaluation to treat diabetes, MS
- more than 700 patents
Financial infusion from Eli Lilly announced today:
- $200 million funding over 4 years
- $75 million equity investment through purchase of ISIP stock at $18/share
- $100 million loan repayable in cash or stock at $40/share
- $25 million upfront fees for license of ISIS 3521
- reimbursement for conducting remaining phase 3 for ISIS 3521
- $50 million in royalties and milestone payments
- If ISIS 3521 is a success, total funds shall exceed all the above
Regards,
Tom |
